{"id":"topical-iop-lowering-drugs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Eye redness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Topical IOP-lowering drugs, such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors, act on the ciliary body to decrease aqueous humor production or increase outflow, thereby reducing intraocular pressure. This mechanism is crucial in managing conditions like glaucoma and ocular hypertension.","oneSentence":"Topical IOP-lowering drugs work by reducing intraocular pressure through the reduction of aqueous humor production or increase in aqueous humor outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:29.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06993597","phase":"","title":"Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-09-01","conditions":"Glaucoma","enrollment":60},{"nctId":"NCT04422743","phase":"NA","title":"Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2018-01-25","conditions":"Glaucoma","enrollment":63},{"nctId":"NCT05456724","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Theratocular Biotek Co.","startDate":"2022-08-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT03624361","phase":"NA","title":"MINIject Glaucoma Implant in European Patients","status":"COMPLETED","sponsor":"iSTAR Medical","startDate":"2018-05-23","conditions":"Glaucoma, Open-Angle, Glaucoma Eye, Intraocular Pressure","enrollment":29},{"nctId":"NCT00934089","phase":"PHASE2","title":"A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":31},{"nctId":"NCT02955849","phase":"EARLY_PHASE1","title":"A Trial of China Laser and Surgery Study Glaucoma in Rural China","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09","conditions":"Glaucoma","enrollment":200},{"nctId":"NCT04523844","phase":"NA","title":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","status":"COMPLETED","sponsor":"General Hospital of Athens Elpis","startDate":"2020-05-11","conditions":"Eye Diseases, Injection Complication, Intraocular Pressure","enrollment":47},{"nctId":"NCT03639675","phase":"PHASE3","title":"Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-03","conditions":"Glaucoma, Neovascular","enrollment":16},{"nctId":"NCT03065036","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG","status":"COMPLETED","sponsor":"Ivantis, Inc.","startDate":"2010-03","conditions":"Primary Open Angle Glaucoma","enrollment":120},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01639807","phase":"NA","title":"Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP","status":"UNKNOWN","sponsor":"Aurolab","startDate":"2011-10","conditions":"Glaucoma","enrollment":600},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topical IOP-lowering drugs","genericName":"Topical IOP-lowering drugs","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical IOP-lowering drugs work by reducing intraocular pressure through the reduction of aqueous humor production or increase in aqueous humor outflow. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}